These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1274 related articles for article (PubMed ID: 30115118)

  • 1. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum.
    Jiang J; Zhuo Z; Wang A; Li W; Jiang S; Duan Y; Ren Q; Zhao M; Wang L; Yang S; Awan MUN; Liu Y; Xu J
    Alzheimers Res Ther; 2024 Jul; 16(1):149. PubMed ID: 38961406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B; Wang L; Xu B; Zhang Y;
    Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Ng KP; Therriault J; Kang MS; Pascoal TA; Rosa-Neto P; Gauthier S;
    Transl Neurodegener; 2018; 7():23. PubMed ID: 30311914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
    Nilsson J; Pichet Binette A; Palmqvist S; Brum WS; Janelidze S; Ashton NJ; Spotorno N; Stomrud E; Gobom J; Zetterberg H; Brinkmalm A; Blennow K; Hansson O
    Brain; 2024 Jul; 147(7):2414-2427. PubMed ID: 38325331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial Cerebrospinal Fluid Sampling Reveals Trajectories of Potential Synaptic Biomarkers in Early Stages of Alzheimer's Disease.
    Duits FH; Nilsson J; Zetterberg H; Blennow K; van der Flier WM; Teunissen CE; Brinkmalm A
    J Alzheimers Dis; 2024; 100(s1):S103-S114. PubMed ID: 39121126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.